NeoVax(MI) vaccine developed by Dana-Farber Cancer Institute could be approved soon with promising results in boosting immune response in melanoma patients
Lara Maior
Health
Vyacheslav Lopatin / Alamy / Profimedia
Always see our news on Google
The clinical trial of the personalized vaccine NeoVax(MI) has shown promising results in the treatment of melanoma, generating a strong immune response. The vaccine contains patient-specific neoantigens and is administered together with standard immunotherapies such as nivolumab and ipilimumab. Scientists observed an increase in immune cells after vaccination, indicating effective immune activation. This innovative approach could significantly improve treatments for skin cancer.
Sources
Vaccinul contra unui tip agresiv de cancer, la un pas de a intra pe piață. Rezultatele remarcabile dau speranțe pacienților
Consiliul Concurenței analizează tranzacţia prin care Mehiläinen Oy preia rețeaua de centre mediale Regina Maria
Consiliul Concurenţei analizează preluarea Grupului Regina Maria de către Mehiläinen Oy
Latest News
18:29
Radu Miruță announces that the subway circulation in Bucharest will not be affected by energy restrictions.
18:19
The large stores in Romania are implementing energy-saving measures, such as limiting air conditioning and turning off advertising lights at night.
18:12
The Senate voted to cancel the closure of coal-fired power plants, adopting amendments that allow for their reopening / Ilie Bolojan warns about penalties from the EU
18:07
Finland has obtained the world's first license for the exploitation of an underground repository for used nuclear fuel, announced by the Radiation and Nuclear Safety Authority.
18:07
The APPR Forum asks the Government to suspend the resumption of active anti-hail interventions, citing the lack of independent evaluations and a public impact study.
See more news
NEWS ON THE SAME TOPICS
.webp)
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
